Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.
Alzheimer’s rates are on the rise. How is today’s best treatment, Leqembi (generic lecanemab) doing in the fight against it?
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
The EMA has announced its schedule for reviewing the Alzheimer’s drug Leqembi (lecanemab) for use in Europe. Meanwhile, the U.S. FDA, which already approved the drug, is moving ahead with a new version that doses Leqembi in a better, more convenient fashion for those taking the drug over the long run.
Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.
Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.
Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?
The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.
TEEPA SNOW MOTHERS’ DAY TIPS: Check out these Alzheimer’s care tips for USA’s Mothers’ Day, compiled by Dementia-specialist Teepa Snow and Senior Helpers.
In an Alzheimer’s study, insulin delivered high up in the nasal cavity achieved lasting results in improving memory. Find out why Dr. W. Banks calls this “one of those studies where everything is coming together.”
See how the class of weight loss and diabetes drugs that includes Ozempic and Wegovy have the added benefit of protecting against the development of dementia.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
